Drug Repurposing of Metabolic Agents in Malignant Glioma
AbstractGliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed. View Full-Text
Share & Cite This Article
Seliger, C.; Hau, P. Drug Repurposing of Metabolic Agents in Malignant Glioma. Int. J. Mol. Sci. 2018, 19, 2768.
Seliger C, Hau P. Drug Repurposing of Metabolic Agents in Malignant Glioma. International Journal of Molecular Sciences. 2018; 19(9):2768.Chicago/Turabian Style
Seliger, Corinna; Hau, Peter. 2018. "Drug Repurposing of Metabolic Agents in Malignant Glioma." Int. J. Mol. Sci. 19, no. 9: 2768.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.